Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 9012-9021
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.9012
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.9012
Table 1 Nodular regenerative hyperplasia of the liver during thioguanine therapy
Dosage of thioguanine | 6-TGN level | Observed NRH | Ref. |
About 20 mg per day (18-24 mg) | 278 (68-492) | 0% (0/12) | [20] |
20 mg per day | 564 ± 278 | 0% (0/28) | [18] |
20 mg per day | 802 (106-1092) | 0% (0/13) | [47] |
About 21 mg per day (0.3 mg/kg) | 464 (65-1199) | 6% (7/111) | [48] |
40 mg per day | 807 (105-2545) | 0% (0/11) | [16] |
About 40 mg per day (estimated) | 1230 (530-2310) | 62% (16/26) | [15] |
40-80 mg per day | Unknown | 36% (16/45) | [45] |
Table 2 Other adverse events associated with thioguanine use
Adverse event | Prevalence | Ref. |
GI complaints | 1%-17% | [16,17,19,20,37,38] |
Myelosuppression1 | 1%-15% | [17,20,36,38] |
General malaise | 4%-22% | [17,38] |
Allergic reaction | 1%-6% | [17,33] |
Other AE (e.g., myalgia, alopecia) | 1%-38% | [16,17,19,20,33,36-38] |
Table 3 Summary of included articles with most important study characteristics
Author | Ref. | Year | Score1 | Number of patients | Number of IBD (CD/UC/IBDu) | Dose (med) | Follow-up (M) | Effective n (%) | Non-effective n (%) | Discontinuation | 6-TGN (med) |
n (%) | |||||||||||
Dubinsky | 17 | 2001 | Very low | 10 | 10/0/0 | 40 | 4 | 7 (70) | 1 (10) | 2 (20) | 15482 |
Cheung | 18 | 2003 | Very low | 15 | 13/1/1 | 40 | 3 | 12 (79) | 1 (7) | 2 (14) | N/A |
Herrlinger | 19 | 2003 | Low | 37 | 37/0/0 | 40 | 6 | 21 (57) | 7 (19) | 9 (24) | N/A |
Bonaz | 21 | 2003 | Very low | 49 | 49/0/0 | 20 | 12 | 38 (78)3 | 6 (12) | 5 (10) | 6484 |
Dubinsky | 22 | 2003 | Very low | 21 | 14/7/0 | 20 | 9 | 14 (67) | 3 (14) | 4 (19) | 13651 |
Teml | 23 | 2005 | Low | 20 | 0/14/6 | 20 | 6 | 11 (55) | 3 (15) | 6 (30) | 8164 |
Qasim | 24 | 2007 | Very low | 40 | 28/10/2 | 40 | 6 | 19 (48) | 8 (20) | 13 (32) | N/A |
Ansari | 12 | 2008 | Low | 30 | 30/0/0 | 40 | 6 | 18 (60) | 5 (17) | 7 (23) | 8074 |
Almer | 25 | 2009 | Low | 23 | 23/0/0 | 40 | 9 | 5 (22) | 5 (22) | 13 (56) | 11552 |
Asseldonk | 16 | 2011 | Low | 46 | 0/46/0 | 20 | 22 | 37 (80)3 | 3 (7) | 6 (13) | 2784 |
Pavlidis | 15 | 2014 | Moderate | 62 | 21/41/0 | 20 | 6 | 46 (78) | 11 (14) | 5 (8) | 8114 |
Table 4 Summary of results of included articles in the total group, as well as different disease groups n (%)
Total number of patients | CD | UC | IBDu | Daily dose (mg)1 | Treatment years2 | Benefit3 | No benefit | Discontinuation | |
353 | 225 (64) | 119 (34) | 9 (2) | 20 | 268 | 228 (65) | 53 (15) | 72 (20) | |
[10-80] | |||||||||
Discontinuation | Response unknown4 | ||||||||
Crohn’s disease (n = 225) | 141 | 118 (52) | 25 (11) | 40 (18) | 42 (19) | ||||
Ulcerative colitis (n = 119) | 122 | 73 (62) | 16 (13) | 11 (9) | 19 (16) |
- Citation: Meijer B, Mulder CJ, Peters GJ, van Bodegraven AA, de Boer NK. Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review. World J Gastroenterol 2016; 22(40): 9012-9021
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/9012.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.9012